The IDH1 and IDH2 mutations area is also prevalent in AML (occur in ~20% of cases) but there are still conflicting data, whether they represent pre-leukemic mutations or dominant clonal mutations, hence their value in monitoring MRD is not yet well established [75,110,112,113]. This evidence concerns the gene IDH1 and acute myeloid leukemia.